Join to View Full Profile
1665 Aurora CTMail Stop F704 Anschutz Cancer Pavilion Acp CP 5328Aurora, CO 80045
Phone+1 858-722-9600
Dr. Shagisultanova is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
St Mary's Hospital and Medical CenterResidency, Internal Medicine, 2009 - 2012
Bashkir State Med UnivClass of 1997
Certifications & Licensure
CO State Medical License 2015 - 2027
CA State Medical License 2011 - 2025
PA State Medical License 2012 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer Start of enrollment: 2017 Nov 27
Publications & Presentations
PubMed
- Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer.Elena Shagisultanova, Hannah Parris, Long Liu, Stephanie Giangiuli, Dexiang Gao
Clinical Breast Cancer. 2025-06-11 - 2 citationsClinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer.Anthony D Elias, Alyse W Staley, Monica Fornier, Gregory A Vidal, Vida Alami
NPJ Breast Cancer. 2024-10-06 - 5 citationsSafety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.Elena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, Pavani Chalasani, Andrew J Brenner
Clinical Cancer Research. 2023-12-15
Press Mentions
How Combining Drugs May Be More Effective at Treating HER2-Positive Breast CancerJanuary 3rd, 2025
Tucatinib (ONT-380) Progressing in Pivotal Trial Against HER2+ Breast CancerJanuary 10th, 2017- Tablets Show Promise as an Alternative to Chemotherapy in CU Cancer Center Member’s Breast Cancer StudyFebruary 1st, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
